Amgen Inc.
AMGN
Xếp hạng trong cổ phiếu
#72
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Giá cổ phiếu
$436.87
Vốn hóa thị trường
$236.19B
Thay đổi (1 ngày)
2.81%
Thay đổi (1 năm)
44.02%
Quốc gia
US
Giao dịch Amgen Inc. (AMGN)
Danh mục
Healthcare
Thu nhập của Amgen Inc. (AMGN)
Thu nhập trong Jun 2026 TTM: $10.29B
Theo báo cáo tài chính gần đây của Amgen Inc., lợi nhuận hiện tại của công ty là $10.29B. Năm 2024, công ty đạt được lợi nhuận là $4.61B, giảm so với lợi nhuận năm 2023 là $7.86B. Lợi nhuận hiển thị trên trang này là lợi nhuận trước lãi vay và thuế, hay còn gọi là EBIT.
Lịch sử thu nhập của Amgen Inc. từ 2000 đến 2026
Thu nhập vào cuối mỗi năm
| Năm | Thu nhập | Thay đổi |
|---|---|---|
| 2026 (TTM) | $10.29B | 14.61% |
| 2025 | $8.98B | 94.75% |
| 2024 | $4.61B | -41.32% |
| 2023 | $7.86B | 6.93% |
| 2022 | $7.35B | 9.63% |
| 2021 | $6.70B | -17.61% |
| 2020 | $8.13B | -11.00% |
| 2019 | $9.14B | -4.26% |
| 2018 | $9.55B | -0.54% |
| 2017 | $9.60B | 4.74% |
| 2016 | $9.16B | 14.85% |
| 2015 | $7.98B | 42.85% |
| 2014 | $5.59B | 6.08% |
| 2013 | $5.27B | 5.11% |
| 2012 | $5.01B | 20.70% |
| 2011 | $4.15B | -21.95% |
| 2010 | $5.32B | 2.17% |
| 2009 | $5.20B | -0.88% |
| 2008 | $5.25B | 32.54% |
| 2007 | $3.96B | -1.47% |
| 2006 | $4.02B | -17.42% |
| 2005 | $4.87B | 43.39% |
| 2004 | $3.40B | 6.99% |
| 2003 | $3.17B | -563.56% |
| 2002 | $-684.50M | -140.59% |
| 2001 | $1.69B | 0.72% |
| 2000 | $1.67B | 0.00% |
Thu nhập của các công ty hoặc đối thủ tương tự
| Công ty | Thu nhập | Chênh lệch thu nhập | Quốc gia |
|---|---|---|---|
| $33.60B | 226.58% |
US
|
|
| $17.74B | 72.42% |
US
|
|
| $8.70B | -15.44% |
US
|
|
| $5.95B | -42.18% |
US
|
|
| $21.39B | 107.92% |
CH
|
